Vibegron - A Novel Treatment for Multisystem Functional Decline in Aging and Obesity
Status:
NOT_YET_RECRUITING
Trial end date:
2028-07-01
Target enrollment:
Participant gender:
Summary
This 12-week randomized, double-blind, placebo-controlled trial will test the hypothesis that Vibegron (brand name GEMTESA) can improve energy metabolism, cardiometabolic risk factors, and physical and cognitive function in middle-aged and older adults with obesity.